Tamoxifen and risk of idiopathic venous thromboembolism

British Journal of Clinical Pharmacology

Volumn 45, Issue 6, 1998, Pages 608-612

  Meier, Christoph R ^a   Jick, Hershel ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Idiopathic venous thromboembolism; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING; THROMBOEMBOLISM; UNITED KINGDOM; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; RISK FACTORS; TAMOXIFEN; THROMBOEMBOLISM;

EID: 0031811978     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00733.x     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988; 319: 1681-1692.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15 and 71-85.
3. Catherino WH, Craig Jordan V. A risk-benefit assessment of tamoxifen therapy. Drug Safety 1993; 8: 381-397.
4. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7: 803-815.
5. McDonald CC, Stewart HJ for the Scottish Breast Cancer Committee. Br Med J 1991; 303: 435-437.
6. Rutqvist LE, Mattsson A. for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398-1406.
7. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995; 87: 645-651.
8. van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-452.
9. Cutuli BF, Tritsch L, Jung GM, Mantz JM. Embolie pulmonaire mortelle chez une malade eu cours de traitement adjuvant par tamoxifene. La Presse Medicale 1991; 20: 1948-1949.
10. Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis. Lancet 1978: i 946-947.
11. Hendrick A, Subramanian VP. Tamoxifen and thromboembolism. JAMA 1980; 243: 514-515.
12. Wilson CB, Lambert HE, Scott RD. Subclavian and axillary vein thrombosis following radiotherapy for carcinoma of the breast. Clin Radiol 1987; 38: 95-96.
13. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
14. Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 1989; 7: 572-582.
15. Saphner T., Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-294.
16. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ for the Scottish Cancer Trials Breast Group. Br Med J 1995; 311: 977-980.
17. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996; 88: 1828-1833.
18. Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J, for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-2737.
19. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors. J Natl Cancer Inst 1996; 88: 1529-1542.
20. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766-768.
21. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiology and Drug Safety 1992; 1: 347-349.
22. Jick H, Jick S, Derby LE, Vasilakis C, Wald Myers M, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-528.
23. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
24. Cutuli B, Petit JC, Fricker JP, Schumacher C, Velten M, Abecassis J. Accidents thromboemboliques chez les patientes menopausees sous traitement adjuvant par tamoxifene. Frequence, facteurs de risque et possibilites de prevention. Bull Cancer 1995; 82: 51-56.
25. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagulation & Fibrinolysis 1993; 4: 935-942.
26. Daly E, Vessey MP, Hawkins MM, Carlson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
27. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. The risk of hospitalization for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996; 348: 981-983.
28. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
29. Pérez Gutthann S, Garca Rodrguez LA, Castellsague Pique J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997; 314: 796-800.
30. Enck RE, Rios CN. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 1984; 53: 2607-2609.
31. Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer 1988; 61: 1316-1319.
32. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 1992; 152: 317-320.
33. Manuucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996; 156: 1806-1810.